WINT News and Press, Windtree Therapeutics Inc. From 08/28/22

Summary According to a Wall Street Journal report, China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. Lee's Pharm of Hong Kong entered a $78.9 million deal with Windtree Therapeutics for global rights ...

3 Popular Penny Stocks to Add to Your Watchlist Right Now Whether penny stocks are worth buying or not is a highly debated topic. Some investors argue that penny stocks provide an opportunity to make a quick profit, while others believe that they’re too risky and not worth th...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: sfam_photo / Shutterstock.com Windtree Therapeutics (NASDAQ: WINT ) is one of the biggest stock movers on Tuesday after announcing a new global licensing agreement for AEROSURF. AEROSURF is the compa...

Windtree may receive up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties Development and all other costs to be assumed by Lee’s Pharmaceutical and Zhaoke Pharmaceutical WARRINGTON, Pa., Aug. 23, 2022 (GLOBE NEWSWI...

Windtree TherapeuticS press release ( NASDAQ: WINT ): Q2 GAAP EPS of -$0.59. As of June 30, 2022, the Company reported cash and cash equivalents of $11.4 million, which is expected to be sufficient to fund operations into the first quarter of 2023. For furt...

WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ende...

3 Penny Stocks to Watch This Week If you’re thinking about buying penny stocks, there are a few things you should know before you get started. The first thing to consider when it comes to investing in penny stocks is what is causing market movement. Because penny stocks are s...

Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions fo...

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours The study also met several key secondary endpo...

WARRINGTON, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced management will host a conference call and webcast...